Identifying the immune interactions underlying HLA class I disease associations
Abstract
Variation in the risk and severity of many autoimmune diseases, malignancies and infections is strongly associated with polymorphisms in the HLA class I loci. These genetic associations provide a powerful opportunity for understanding the etiology of human disease. HLA class I associations are often interpreted in the light of 'protective' or 'detrimental' CD8+ T cell responses which are restricted by the host HLA class I allotype. However, given the diverse receptors which are bound by HLA class I molecules, alternative interpretations are possible. As well as binding T cell receptors on CD8+ T cells, HLA class I molecules are important ligands for inhibitory and activating killer immunoglobulin-like receptors (KIRs) which are found on natural killer cells and some T cells; for the CD94:NKG2 family of receptors also expressed mainly by NK cells and for leukocyte immunoglobulin-like receptors (LILRs) on myeloid cells. The aim of this study is to develop an immunogenetic approach for identifying and quantifying the relative contribution of different receptor-ligand interactions to a given HLA class I disease association and then to use this approach to investigate the immune interactions underlying HLA class I disease associations in three viral infections: Human T cell Leukemia Virus type 1, Human Immunodeficiency Virus type 1 and Hepatitis C Virus as well as in the inflammatory condition Crohn's disease.
Data availability
Upon acceptance we will upload, to a public database, all the data analysis ie the data underlying Figure 1, Figure 2, Figure 3, Supplementary Figure S1, Supplementary Figure S2, Supplementary Figure S3 and Supplementary Figure S4. We are unable to provide the raw patient data as this has been released to us under MTAs and uploading of data would violate the terms of these MTAs.The PIs we contacted for the various cohorts are: Pat Fast, IAVI, New York (IAVI); Charles Bangham, Imperial College London, UK (Kagoshima cohort); Greg Kirk, Johns Hopkins, USA (ALIVE cohort); James Goedert, NIH (MHCS cohort); Sharyne Donfield, Rho, USA (HGDS cohort); Salim Khakoo, University of Southampton, UK (UK HCV cohort) and James Lee, University of Cambridge, UK (Crohn's disease cohort). Requests for data access and usage are reviewed by the relevant boards at each institution.
Article and author information
Author details
Funding
Wellcome (103865Z/14/Z)
- Becca Asquith
National Institutes of Health (R01-DA-12568)
- Gregory Kirk
National Institutes of Health (K24-AI118591)
- Gregory Kirk
Medical Research Council (J007439)
- Becca Asquith
Medical Research Council (G1001052)
- Becca Asquith
European Commission (317040)
- Becca Asquith
Bloodwise (15012)
- Becca Asquith
Wellcome (105920/Z/14/Z)
- James C Lee
National Institutes of Health (DA13324)
- Chloe L Thio
National Institutes of Health (R01-HD-41224)
- Sharyne M Donfield
National Institutes of Health (U01-DA-036297)
- Gregory Kirk
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Miles P Davenport, University of New South Wales, Australia
Ethics
Human subjects: This study was approved by the NHS Research Ethics Committee (13/WS/0064) and the Imperial College Research Ethics Committee (ICREC_11_1_2). Informed consent was obtained at the study sites from all individuals. The study was conducted according to the principles of the Declaration of Helsinki.
Version history
- Received: December 18, 2019
- Accepted: March 6, 2020
- Accepted Manuscript published: April 2, 2020 (version 1)
- Version of Record published: May 27, 2020 (version 2)
Copyright
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Metrics
-
- 5,058
- views
-
- 546
- downloads
-
- 18
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
- Computational and Systems Biology
Circular RNAs represent a class of endogenous RNAs that regulate gene expression and influence cell biological decisions with implications for the pathogenesis of several diseases. Here, we disclose a novel gene-regulatory role of circHIPK3 by combining analyses of large genomics datasets and mechanistic cell biological follow-up experiments. Using time-course depletion of circHIPK3 and specific candidate RNA-binding proteins, we identify several perturbed genes by RNA sequencing analyses. Expression-coupled motif analyses identify an 11-mer motif within circHIPK3, which also becomes enriched in genes that are downregulated upon circHIPK3 depletion. By mining eCLIP datasets and combined with RNA immunoprecipitation assays, we demonstrate that the 11-mer motif constitutes a strong binding site for IGF2BP2 in bladder cancer cell lines. Our results suggest that circHIPK3 can sequester IGF2BP2 as a competing endogenous RNA (ceRNA), leading to target mRNA stabilization. As an example of a circHIPK3-regulated gene, we focus on the STAT3 mRNA as a specific substrate of IGF2BP2 and validate that manipulation of circHIPK3 regulates IGF2BP2-STAT3 mRNA binding and, thereby, STAT3 mRNA levels. Surprisingly, absolute copy number quantifications demonstrate that IGF2BP2 outnumbers circHIPK3 by orders of magnitude, which is inconsistent with a simple 1:1 ceRNA hypothesis. Instead, we show that circHIPK3 can nucleate multiple copies of IGF2BP2, potentially via phase separation, to produce IGF2BP2 condensates. Our results support a model where a few cellular circHIPK3 molecules can induce IGF2BP2 condensation, thereby regulating key factors for cell proliferation.
-
- Cell Biology
- Computational and Systems Biology
Bats have unique characteristics compared to other mammals, including increased longevity and higher resistance to cancer and infectious disease. While previous studies have analyzed the metabolic requirements for flight, it is still unclear how bat metabolism supports these unique features, and no study has integrated metabolomics, transcriptomics, and proteomics to characterize bat metabolism. In this work, we performed a multi-omics data analysis using a computational model of metabolic fluxes to identify fundamental differences in central metabolism between primary lung fibroblast cell lines from the black flying fox fruit bat (Pteropus alecto) and human. Bat cells showed higher expression levels of Complex I components of electron transport chain (ETC), but, remarkably, a lower rate of oxygen consumption. Computational modeling interpreted these results as indicating that Complex II activity may be low or reversed, similar to an ischemic state. An ischemic-like state of bats was also supported by decreased levels of central metabolites and increased ratios of succinate to fumarate in bat cells. Ischemic states tend to produce reactive oxygen species (ROS), which would be incompatible with the longevity of bats. However, bat cells had higher antioxidant reservoirs (higher total glutathione and higher ratio of NADPH to NADP) despite higher mitochondrial ROS levels. In addition, bat cells were more resistant to glucose deprivation and had increased resistance to ferroptosis, one of the characteristics of which is oxidative stress. Thus, our studies revealed distinct differences in the ETC regulation and metabolic stress responses between human and bat cells.